The committee endorsed lowering the age at which some people can receive RSV vaccines, but stopped short of recommending booster shots.

RSV vaccines could get broader CDC backing for adults aged 50-59 at risk after an endorsement from an agency's expert panel. Read more here.

A complaint against GSK accusing it of a major breach of the pharma industry's code of practice on prescribing information has been upheld after a review by the Prescription Medicines Code of Practice ...

A key group of government advisers voted to expand the use of vaccines for a common respiratory illness, providing a boost to ...

The Advisory Committee on Immunization Practices voted Wednesday to recommend lowering the age at which adults can get a ...

The CDC's Advisory Committee on Immunization Practices (ACIP) voted 14-0, with one abstention, on Wednesday to recommend that ...

If the tariff-loving Trump goes ahead with his plans, it will hit AstraZeneca - the most valuable company on the UK stock ...

Guidelines from the Advisory Committee on Immunization Practices help physicians decide what vaccines to recommend to ...

The market is characterized by trends such as personalized medicine, targeted therapies, and combination treatments. Key players include Eli Lilly, Bristol Myers Squibb, and AstraZeneca. As North ...

Lower operating costs and a supply of high-skilled workers are helping the North Carolina region pull in billions of pharma ...

Johnson & Johnson’s Joaquin Duato is no longer the highest paid CEO in pharma. Meanwhile, just two women make the top 10.

Parts of DaVita's network were locked down by the attack, and the company has not yet provided a timeline for recovery. DaVita works with over 700 U.S. hospitals providing kidney dialysis. In pharma ...